Compare INCY & NWSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCY | NWSA |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.9B |
| IPO Year | 1993 | N/A |
| Metric | INCY | NWSA |
|---|---|---|
| Price | $100.64 | $26.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | ★ $94.94 | $37.95 |
| AVG Volume (30 Days) | 2.2M | ★ 3.7M |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.76% |
| EPS Growth | ★ 3878.02 | 230.83 |
| EPS | ★ 5.90 | 2.06 |
| Revenue | $4,813,105,000.00 | ★ $8,500,000,000.00 |
| Revenue This Year | $19.59 | $5.10 |
| Revenue Next Year | $10.80 | $3.24 |
| P/E Ratio | $17.09 | ★ $12.82 |
| Revenue Growth | ★ 18.09 | 2.20 |
| 52 Week Low | $53.56 | $23.38 |
| 52 Week High | $109.28 | $31.61 |
| Indicator | INCY | NWSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 55.83 |
| Support Level | $97.01 | $25.80 |
| Resistance Level | $103.45 | $26.45 |
| Average True Range (ATR) | 3.27 | 0.44 |
| MACD | 0.11 | 0.09 |
| Stochastic Oscillator | 70.32 | 84.91 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.